10 Stocks Bleeding Early

Ten stocks led a lackluster performance on Monday, defying a broader market optimism, amid a series of company-specific news that included dismal earnings and a lower growth outlook, among others.

Meanwhile, Wall Street’s main indices all finished in the green, with the Dow Jones up by 1.3 percent, the S&P 500 jumped by 1.5 percent, and the Nasdaq increased by 1.9 percent.

In this article, we name the 10 worst-performing stocks on Monday and highlight the reasons behind their drop.

To compile the list, we focused on stocks with at least $2 billion in capitalization and more than 5 million shares in trading volume.

Photo by George Morina on Pexels

10. Macy’s Inc. (NYSE:M)

Macy’s Inc. extended its losing streak to a fifth consecutive day on Monday, shedding 3.72 percent to close at $11.9 apiece, as investors unloaded portfolios ahead of the release of its earnings performance for the second quarter of the year.

Based on its historical reporting dates, Macy’s Inc. (NYSE:M) will release the results of its financial and operating highlights for the second quarter in the third week of August, or two weeks from now.

However, the recent share price decline suggested a more cautious trading sentiment following a recent restructuring initiative that included the closure of 150 stores over a three-year period.

Of the total, Macy’s Inc. (NYSE:M) plans to close 66 stores this year, and impact its net sales in the second quarter of the year versus the same period last year.

In the first quarter of the year, Macy’s Inc. (NYSE:M) saw its net income decline by 39 percent to $38 million from $62 million in the same period last year.

Total revenues decreased by 4.2 percent to $4.79 billion from $5 billion year-on-year.

9. DexCom, Inc. (NASDAQ:DXCM)

DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company’s strong earnings performance in the second quarter of the year.

In a statement last week, DexCom, Inc. (NASDAQ:DXCM) named Jake Leach as its new chief executive officer (CEO) effective January 1, 2026, in addition to his post as the current president and chief operating officer.

Incumbent CEO Kevin Sayer will continue to work closely with Leach during the transition period and remain executive chairman of the board of directors.

Meanwhile, DexCom, Inc. (NASDAQ:DXCM) grew its net income in the second quarter of the year by 25 percent to $179.8 million from $143.5 million in the same period last year. Revenues increased by 16 percent to $1.16 billion from $1 billion year-on-year.